{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:35:08Z","timestamp":1769848508642,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01263-3","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T17:00:58Z","timestamp":1751907658000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Toripalimab in Esophageal Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"56","author":[{"given":"Mostafa A.","family":"Khalifa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marafi Jammaa","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hashim Talib","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya Ahmed","family":"Shimal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad Omar","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma","family":"Allam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elian Khalafalla","family":"Awadalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadeel Basheer Bin","family":"Saud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jubran Khaled","family":"Alzedaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Dway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roaa","family":"Abdultawab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asala Hussein","family":"Al-hadrawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammedbaqer","family":"Ghuraibawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"1263_CR1","doi-asserted-by":"crossref","unstructured":"Qi L, Sun M, Liu W, Zhang X, Yu Y, Tian Z, et al. Global esophageal cancer epidemiology in 2022 and predictions for 2050: A comprehensive analysis and projections based on GLOBOCAN data. Chin Med J (Engl) [Internet]. 2024 Dec 20 [cited 2025 Apr 10];137(24). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39668405\/","DOI":"10.1097\/CM9.0000000000003420"},{"key":"1263_CR2","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin [Internet]. 2022 Jan [cited 2025 Jan 18];72(1):7\u201333. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35020204\/","DOI":"10.3322\/caac.21708"},{"key":"1263_CR3","doi-asserted-by":"crossref","unstructured":"Christodoulidis G, Agko SE, Koumarelas KE, Kouliou MN, Zacharoulis D. Advancements and challenges in the treatment of esophageal cancer: A comprehensive review. World J Clin Oncol [Internet]. 2024 Dec 24 [cited 2025 Jan 18];15(12):1463\u20137. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39720647","DOI":"10.5306\/wjco.v15.i12.1463"},{"key":"1263_CR4","doi-asserted-by":"publisher","unstructured":"Chen L, Wang H, Qi Z, Liang L, Guo C, He Y, et al. Dynamics of Long-Term Quality of Life After Treatment for Esophageal Cancer: A Community-Based Patient Study. JCO Glob Oncol [Internet]. 2024 Jul [cited 2025 Jan 18];(10). Available from: https:\/\/ascopubs.org\/doi\/https:\/\/doi.org\/10.1200\/GO.24.00044","DOI":"10.1200\/GO.24.00044"},{"key":"1263_CR5","doi-asserted-by":"crossref","unstructured":"Klevebro F, Johar A, Lagergren P. Impact of co\u2010morbidities on health\u2010related quality of life 10\u2009years after surgical treatment of oesophageal cancer. BJS Open [Internet]. 2020 Aug 1 [cited 2025 Jan 18];4(4):601. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7397362\/","DOI":"10.1002\/bjs5.50303"},{"key":"1263_CR6","doi-asserted-by":"publisher","unstructured":"van der Wilk BJ, Eyck BM, Noordman BJ, Kranenburg LW, Oppe M, Lagarde SM, et al. Characteristics Predicting Short-Term and Long-Term Health-Related Quality of Life in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy and Esophagectomy. Ann Surg Oncol [Internet]. 2023 Dec 1 [cited 2025 Jan 18];30(13):8192\u2013202. Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1245\/s10434-023-14028-8","DOI":"10.1245\/s10434-023-14028-8"},{"key":"1263_CR7","doi-asserted-by":"crossref","unstructured":"Puhr HC, Prager GW, Ilhan-Mutlu A. How we treat esophageal squamous cell carcinoma. ESMO Open [Internet]. 2023 Feb 1 [cited 2025 Jan 18];8(1):100789. Available from: http:\/\/www.esmoopen.com\/article\/S2059702923000091\/fulltext","DOI":"10.1016\/j.esmoop.2023.100789"},{"key":"1263_CR8","doi-asserted-by":"publisher","unstructured":"Zhang Y, Li Z, Huang Y, Xu Y, Zou B. Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions. Expert Rev Clin Immunol [Internet]. 2024 Aug 2 [cited 2025 Apr 10];20(8):971\u201384. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/https:\/\/doi.org\/10.1080\/1744666X.2024.2368194","DOI":"10.1080\/1744666X.2024.2368194"},{"key":"1263_CR9","doi-asserted-by":"crossref","unstructured":"Nagata Y, Yamamoto S, Kato K. Immune checkpoint inhibitors in esophageal cancer: Clinical development and perspectives. Hum Vaccin Immunother [Internet]. 2022 [cited 2025 Apr 10];18(6). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36375821\/","DOI":"10.1080\/21645515.2022.2143177"},{"key":"1263_CR10","unstructured":"FDA Approves Toripalimab for Advanced Nasopharyngeal Cancer - NCI [Internet]. [cited 2025 Jan 18]. Available from: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2024\/fda-toripalimab-nasopharyngeal-cancer"},{"key":"1263_CR11","doi-asserted-by":"crossref","unstructured":"Zhang L, Hao B, Geng Z, Geng Q. Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol [Internet]. 2022 Jan 12 [cited 2025 Jan 18];12:730666. Available from: www.frontiersin.org","DOI":"10.3389\/fimmu.2021.730666"},{"key":"1263_CR12","doi-asserted-by":"crossref","unstructured":"Rajasekaran N, Wang X, Ravindranathan S, Chin DJ, Tseng SY, Klakamp SL, et al. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells. Cancer Immunol Immunother [Internet]. 2024 Mar 1 [cited 2025 Jan 18];73(3). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38400933\/","DOI":"10.1007\/s00262-024-03635-3"},{"key":"1263_CR13","unstructured":"Coherus | Immunotherapy | Toripalimab-tpzi | PD-1 Inhibitor [Internet]. [cited 2025 Jan 18]. Available from: https:\/\/www.coherus.com\/toripalimab-tpzi-pd-1\/?utm_source=chatgpt.com"},{"key":"1263_CR14","doi-asserted-by":"crossref","unstructured":"Zhang L, Hao B, Geng Z, Geng Q. Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol [Internet]. 2022 Jan 12 [cited 2025 Jan 18];12:730666. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8789657\/","DOI":"10.3389\/fimmu.2021.730666"},{"key":"1263_CR15","doi-asserted-by":"crossref","unstructured":"Wang Y, Deng L, Wang J, Zhang T, Wang W, Wang X, et al. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study). Front Immunol [Internet]. 2024 [cited 2025 Jan 18];14. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38288117\/","DOI":"10.3389\/fimmu.2023.1341584"},{"key":"1263_CR16","doi-asserted-by":"crossref","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. JAMA [Internet]. 2023 Nov 28 [cited 2025 Jan 18];330(20):1961\u201370. Available from: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2812324","DOI":"10.1001\/jama.2023.20181"},{"key":"1263_CR17","first-page":"90","volume":"1","author":"G Zhang","year":"2023","unstructured":"Zhang G, Yuan J, Pan C, Xu Q, Cui X, Zhang J, et al. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial. EBioMedicine. 2023;1:90.","journal-title":"EBioMedicine"},{"key":"1263_CR18","first-page":"62","volume":"1","author":"R Chen","year":"2023","unstructured":"Chen R, Liu Q, Li Q, Zhu Y, Zhao L, Liu S, et al. A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901). EClinicalMedicine. 2023;1:62.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"1263_CR19","doi-asserted-by":"publisher","first-page":"478","DOI":"10.21037\/jgo-22-131","volume":"13","author":"L Gao","year":"2022","unstructured":"Gao L, Lu J, Zhang P, Hong ZN, Kang M. Toripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a single-center, single-arm clinical trial (ESONICT-2). J Gastrointest Oncol. 2022;13(2):478\u201387.","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"1263_CR20","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.1093\/oncolo\/oyab011","volume":"27","author":"W He","year":"2022","unstructured":"He W, Leng X, Mao T, Luo X, Zhou L, Yan J, et al. Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma. Oncologist. 2022;27(1):E18-28.","journal-title":"Oncologist"},{"issue":"1","key":"1263_CR21","doi-asserted-by":"publisher","first-page":"e008229","DOI":"10.1136\/jitc-2023-008229","volume":"12","author":"N Jiang","year":"2024","unstructured":"Jiang N, Zhang J, Guo Z, Wu Y, Zhao L, Kong C, et al. Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): A single-arm phase Ib clinical trial. J Immunother Cancer. 2024;12(1):e008229.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1263_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","volume":"40","author":"ZX Wang","year":"2022","unstructured":"Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, et al. Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022;40(3):277-288.e3.","journal-title":"Cancer Cell"},{"key":"1263_CR23","doi-asserted-by":"publisher","unstructured":"Mantziari S, Farinha HT, Messier M, Winiker M, Allemann P, Ozsahin EM, et al. Low-Dose Radiation Yields Lower Rates of Pathologic Response in Esophageal Cancer Patients. Ann Surg Oncol [Internet]. 2024 Apr 1 [cited 2025 Jan 23];31(4):2499\u2013508. Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1245\/s10434-023-14810-8","DOI":"10.1245\/s10434-023-14810-8"},{"key":"1263_CR24","doi-asserted-by":"crossref","unstructured":"Luo Y, Mao Q, Wang X, Yu J, Li M. Radiotherapy for esophageal carcinoma: dose, response and survival. Cancer Manag Res [Internet]. 2017 Dec 29 [cited 2025 Jan 23];10:13\u201321. Available from: https:\/\/www.dovepress.com\/radiotherapy-for-esophageal-carcinoma-dose-response-and-survival-peer-reviewed-fulltext-article-CMAR","DOI":"10.2147\/CMAR.S144687"},{"key":"1263_CR25","doi-asserted-by":"crossref","unstructured":"Yang W, Xing X, Yeung SCJ, Wang S, Chen W, Bao Y, et al. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. J Immunother Cancer [Internet]. 2022 Jan 1 [cited 2025 Jan 23];10(1):e003497. Available from: https:\/\/jitc.bmj.com\/content\/10\/1\/e003497","DOI":"10.1136\/jitc-2021-003497"},{"key":"1263_CR26","doi-asserted-by":"crossref","unstructured":"Shen D, Chen Q, Wu J, Li J, Tao K, Jiang Y. The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma. J Gastrointest Oncol [Internet]. 2021 Feb 1 [cited 2025 Jan 23];12(1):1. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7944149\/","DOI":"10.21037\/jgo-20-599"},{"key":"1263_CR27","doi-asserted-by":"crossref","unstructured":"Qin J, Xue L, Hao A, Guo X, Jiang T, Ni Y, et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial. Nature Medicine 2024 30:9 [Internet]. 2024 Jul 2 [cited 2025 Jan 23];30(9):2549\u201357. Available from: https:\/\/www.nature.com\/articles\/s41591-024-03064-w","DOI":"10.1038\/s41591-024-03064-w"},{"key":"1263_CR28","doi-asserted-by":"crossref","unstructured":"Li ZC, Sun YT, Lai MY, Zhou YX, Qiu MZ. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis. Int Immunopharmacol [Internet]. 2022 Aug 1 [cited 2025 May 30];109. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35504202\/","DOI":"10.1016\/j.intimp.2022.108790"},{"key":"1263_CR29","doi-asserted-by":"crossref","unstructured":"Tian JZ, Zhang L, Lin FY, He RJ, Tian WR, Yan L, et al. The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysis. Front Med (Lausanne) [Internet]. 2024 Jan 10 [cited 2025 May 30];11:1515263. Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_","DOI":"10.3389\/fmed.2024.1515263"},{"key":"1263_CR30","doi-asserted-by":"publisher","unstructured":"Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. Journal of Clinical Oncology [Internet]. 2020 Dec 10 [cited 2025 Jan 23];38(35):4138\u201348. Available from: https:\/\/ascopubs.org\/doi\/https:\/\/doi.org\/10.1200\/JCO.20.01888","DOI":"10.1200\/JCO.20.01888"},{"key":"1263_CR31","doi-asserted-by":"publisher","unstructured":"Benefit of First-Line Pembrolizumab Plus Chemotherapy in Esophageal Cancer Bolstered by Longer-Term Efficacy, Safety, and QOL Data From KEYNOTE-590. Default Digital Object Group [Internet]. 2022 Jan 27 [cited 2025 Jan 23]; Available from: https:\/\/dailynews.ascopubs.org\/do\/https:\/\/doi.org\/10.1200\/ADN.22.200824\/abs\/","DOI":"10.1200\/ADN.22.200824\/abs"},{"key":"1263_CR32","doi-asserted-by":"crossref","unstructured":"Patruni S, Fayyaz F, Bien J, Phillip T, King DA. Immunotherapy in the Management of Esophagogastric Cancer: A Practical Review. JCO Oncol Pract [Internet]. 2022 Mar [cited 2025 Jan 23];19(3):107. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10022879\/","DOI":"10.1200\/OP.22.00226"},{"key":"1263_CR33","doi-asserted-by":"publisher","unstructured":"Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. New England Journal of Medicine [Internet]. 2022 Feb 3 [cited 2025 Jan 23];386(5):449\u201362. Available from: https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa2111380","DOI":"10.1056\/NEJMoa2111380"},{"key":"1263_CR34","doi-asserted-by":"crossref","unstructured":"Adv Pract Oncol J, Barnes Rogers B, Zawislak C, Wong V. Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors. J Adv Pract Oncol [Internet]. 2021 May 1 [cited 2025 Jan 23];12(4):392. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8163252\/","DOI":"10.6004\/jadpro.2021.12.4.4"},{"key":"1263_CR35","unstructured":"Jackson-Carroll N, Whisenant M, Crane S, Johnson C. Impact of Immune Checkpoint Inhibitor Therapy on Quality of Life in Patients With Advanced Melanoma: A Systematic Review. Cancer Nurs [Internet]. 2023 Nov 16 [cited 2025 Apr 10]; Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37976054\/"},{"key":"1263_CR36","doi-asserted-by":"crossref","unstructured":"Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ [Internet]. 2018 Mar 14 [cited 2025 Apr 10];360:793. Available from: https:\/\/www.bmj.com\/content\/360\/bmj.k793","DOI":"10.1136\/bmj.k793"},{"key":"1263_CR37","doi-asserted-by":"crossref","unstructured":"Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nature Reviews Drug Discovery 2021 21:7 [Internet]. 2021 Jul 27 [cited 2025 Apr 10];21(7):495\u2013508. Available from: https:\/\/www.nature.com\/articles\/s41573-021-00259-5","DOI":"10.1038\/s41573-021-00259-5"},{"key":"1263_CR38","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol [Internet]. 2018 Jun 10 [cited 2025 Apr 10];36(17):1714. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6481621\/"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01263-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01263-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01263-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:08:29Z","timestamp":1752138509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01263-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1263"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01263-3","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"14 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}